475272-16-3

Upstream product

• 41876-52-2 2-benzyl-4-bromoanisole 

Downstream Products

• 475094-55-4 3-(3'-Benzyl-4-(carboxymethoxy)-2,3-diisobutyl-1,1':4',1-terphenyl-4-yl)propanoic acid 
• 475272-35-6 3-(3'-benzyl-4''-(cyanomethoxy)-2,3''-diisobutyl-1,1':4',1''-terphenyl-4-yl)propanenitrile 
• 475272-34-5 3-(3'-benzyl-2,3''-4''-hydroxy-diisobutyl-1,1':4',1''-terphenyl-4-yl)propanenitrile 
• 475272-33-4 3-(3'-benzyl-2,3''-diisobutyl-4''-methoxy-1,1':4',1''-terphenyl-4-yl)propanenitrile 
• 475272-20-9 trifluoro-methanesulfonic acid 3-benzyl-4'-(2-cyanoethyl)-2'-isobutyl-biphenyl-4-yl ester 
• 475272-19-6 3-(3'-benzyl-4'-hydroxy-2-isobutyl-1,1'-biphenyl-4-yl)propanenitrile 
• 475272-18-5 3-(3'-benzyl-2-isobutyl-4'-methoxy-1,1'-biphenyl-4-yl)propanenitrile 

Relevant academic research and scientific papers

Proteomimetic compounds and methods

The present invention relates to compounds and pharmaceutical compositions which are proteomimetic and to methods for inhibiting the interaction of an alpha-helical protein with another protein or binding site. Methods for treating diseases or conditions which are modulated through interactions between alpha helical proteins and their binding sites are other aspects of the invention.